This NDC is on FDA's drug shortage list (posted Apr 7, 2020)
Product Information
FUROSEMIDE 20 MG/2 ML VIAL is a generic product labeled by Baxter Healthcare Corporation, priced at $0.4901 per ML under NDC 36000028225. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Jan 27, 2014. Its Orange Book therapeutic-equivalence code is AP.
Strength
10 mg/mL
Manufacturer
Baxter Healthcare CorporationNDC
36000028225
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
FUROSEMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA202747FDA Approved
1/27/2014
TE Code
AP
On Market Since
2/6/2014
Pharmacological Classes
Price Statistics
The NADAC for FUROSEMIDE 20 MG/2 ML VIAL has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 21.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4901 per ML |
|---|---|
| All-time high | $0.6277 (May 15, 2024) |
| All-time low | $0.3473 (Dec 17, 2025) |
| 52-week high | $0.4901 |
| 52-week low | $0.3473 |
| Median price | $0.4073 |
| Average price | $0.4375 |
| Largest weekly change | -22.5% (Dec 18, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 52% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Baxter Healthcare Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
furosemide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Loop Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FUROSEMIDE 20 MG/2 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for FUROSEMIDE 20 MG/2 ML VIAL, manufactured by Baxter Healthcare Corporation, is $0.4901 per ML (NDC 36000028225), effective Sep 30, 2026.
How has the price of FUROSEMIDE 20 MG/2 ML VIAL changed over time?
Over the history we have for it, the NADAC for FUROSEMIDE 20 MG/2 ML VIAL has declined 21.9%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for FUROSEMIDE 20 MG/2 ML VIAL?
Since Apr 17, 2024, the NADAC for FUROSEMIDE 20 MG/2 ML VIAL has ranged from a low of $0.3473 (Dec 17, 2025) to a high of $0.6277 (May 15, 2024), with a median of $0.4073 per ML.
Are there cheaper alternatives to FUROSEMIDE 20 MG/2 ML VIAL?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FUROSEMIDE 40 MG/4 ML VIAL, is $0.2334 per ML — about 52% below FUROSEMIDE 20 MG/2 ML VIAL.
Who manufactures FUROSEMIDE 20 MG/2 ML VIAL?
FUROSEMIDE 20 MG/2 ML VIAL (NDC 36000028225) is labeled by Baxter Healthcare Corporation, and CMS classifies it as a generic product.
Is FUROSEMIDE 20 MG/2 ML VIAL in shortage?
Yes — NDC 36000028225 is currently listed in FDA's drug shortage database (posted Apr 7, 2020).